Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it ...

GSK (GSK) plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization, STAT’s John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s intraday trade. The stock rose after the company reported its second quarter ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

Sales of GSK’s top-selling vaccines fell sharply during the third quarter amid lower demand, sending shares in the British pharmaceutical company down 3% in U.S. trading Wednesday. GSK, which had ...